OncoMatch/Clinical Trials/NCT06031246
Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018)
Is NCT06031246 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for lung adenocarcinoma.
This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1018. The goal of this clinical trial is to confirm the theraputic effect of selective lymph node dissection for cT1N0M0 invasive non-small cell lung cancer with CTR\>0.5 located in the apical segment. The main questions it aims to answer are: The 5-year overall survival of patients having cT1N0M0 invasive non-small cell lung cancer with CTR\>0.5 located in the apical segment; The post-operative lymph node metastasis and recurrence-free survival. Participants will receive selective lymph node dissection as the surgical procedure.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage CT1N0M0
Excluded: Stage NOT CT1N0M0
Resectable peripheral cT1N0M0 tumors with CTR>0.5 located in the apical segment; Not cT1N0M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: lung cancer surgery
Cannot have received: chemotherapy
Cannot have received: radiotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify